XTX Topco Ltd Raises Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

XTX Topco Ltd boosted its stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 41.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 157,642 shares of the company’s stock after buying an additional 46,397 shares during the quarter. XTX Topco Ltd owned approximately 0.09% of X4 Pharmaceuticals worth $106,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Verition Fund Management LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth about $30,000. SG Americas Securities LLC acquired a new stake in X4 Pharmaceuticals during the third quarter worth approximately $37,000. Rhumbline Advisers grew its stake in X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the period. Jane Street Group LLC grew its stake in X4 Pharmaceuticals by 103.4% in the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after acquiring an additional 126,296 shares during the period. Finally, AQR Capital Management LLC raised its holdings in X4 Pharmaceuticals by 1,080.3% in the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after acquiring an additional 388,115 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on XFOR. HC Wainwright lowered their price objective on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus dropped their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80. Following the transaction, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. The trade was a 18.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at approximately $257,674.20. This represents a 13.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 580,800 shares of company stock valued at $321,447. Company insiders own 1.62% of the company’s stock.

X4 Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ XFOR opened at $0.61 on Friday. The stock has a market capitalization of $104.03 million, a PE ratio of -6.78 and a beta of 0.35. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a fifty day moving average of $0.50 and a 200-day moving average of $0.65. X4 Pharmaceuticals, Inc. has a 52-week low of $0.26 and a 52-week high of $1.60.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.